FDA partners with Aetion to analyze 'real world' COVID-19 data from EHRs, insurance claims, patient registries

The FDA tapped New York-based health tech startup Aetion to identify and analyze "real-world" data sources to better understand COVID-19 disease symptoms, immunity and potential treatments. 

The FDA and Aetion will pull data from sources including EHRs, insurance claims, patient registries and lab results. By evaluating this data, the partners aim to answer questions about the use of diagnostics and medications in the pandemic as well as risk factors for COVID-19-related complications in different patient populations. 

"Evaluation of real-world data has the potential to provide a wealth of rapid, actionable information to better understand disease symptoms, describe and measure immunity and understand available medical product supplies to help mitigate potential shortages," the FDA news release states. 

Through the research, FDA aims to support ongoing work to evaluate potential therapies, vaccines and diagnostics for COVID-19. The agency also plans to use the data to reduce potential medical product and food supply chain shortages as well as verify safety and quality of FDA-regulated products. 

More articles on data analytics: 
Florida's COVID-19 dashboard creator claims she was fired for refusing to 'manipulate' data
Optum, Health Catalyst Capital lead $21.5M funding round for data analytics company: 4 things to know
Texas hospital district deploys system to collect, share COVID-19 data in real time

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

 

Featured Content

Featured Webinars

Featured Whitepapers